Roosin Collagen Powder
Roosin Medical Co., Ltd. · Decision date Jun 3, 2026
What did the FDA decide?
FDA records K254034 as a 510(k) premarket notification, with a decision dated Jun 3, 2026. The decision code SESE records a finding of substantial equivalence. This is a 510(k) clearance.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- Unknown
- Decision date
- Jun 3, 2026
Regulatory record facts
- Identifier
- K254034
- Regulatory pathway
- 510(k) premarket notification
- Applicant
- Roosin Medical Co., Ltd.
- Product code
- KGN
- Decision code
- SESE
- Decision date
- Jun 3, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Wound Dressing With Animal-Derived Material(S).
- Applicant
- Roosin Medical Co., Ltd.
- Product code
- KGN
- FDA device class
- U
FDA decision timeline
K254034 received
Application receipt date recorded by FDA.
K254034 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
Other records with product code KGN
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Kerecis Express (50250)K260058 | Kerecis Limited | 510(k) clearance | Oct 30, 2026 | FDA |
| Berkeley Advanced Biomaterials | 510(k) clearance | Oct 22, 2026 | FDA | |
epi-ConneKt Wound MatrixK260530 | MLM Biologics, Inc. | 510(k) clearance | Oct 15, 2026 | FDA |
ColActive PlusK260652 | Covalon Technologies, Ltd. | 510(k) clearance | Sep 9, 2026 | FDA |
| Berkeley Advanced Biomaterials | 510(k) clearance | Aug 27, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Roosin Medical Co., Ltd.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Taizhou
Sources and methodology
- Original FDA record: K254034
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records

